Initial Findings from a High Genetic Risk Prostate Cancer Clinic - 30/10/21
ABSTRACT |
Objective |
To improve prostate cancer screening for high-risk men, we developed an early detection clinic for patients at high genetic risk of developing prostate cancer. Despite the rapidly growing understanding of germline variants in driving aggressive prostate cancer and the increased availability of genetic testing, there is little evidence surrounding how best to screen these men.
Methods |
We are reporting on the first 45 patients enrolled, men between the ages of 35–75, primarily with known pathogenic germline variants in prostate cancer susceptibility genes. Screening consists of an intake lifestyle survey, PSA, DRE, and SelectMDx urine assay. A biopsy was recommended for any of the following indications: 1) abnormal DRE, 2) PSA above threshold, or 3) SelectMDx above threshold. The primary outcomes were number needed to screen, and number needed to biopsy to diagnose a patient with prostate cancer.
Results |
Patients enrolled in the clinic included those with BRCA1 (n=7), BRCA2 (n=16), Lynch Syndrome (n=6), and CHEK2 (n = 4) known pathogenic germline variants. The median age and PSA were 58 (range 35–71) and 1.4 ng/ml (range 0.1–11.4 ng/ml), respectively. 12 patients underwent a prostate needle biopsy and there were 4positive biopsies for prostate cancer.
Conclusion |
These early data support the feasibility of opening a dedicated clinic for men at high genetic risk of prostate cancer. This early report on the initial enrollment of our long-term study will help optimize early detection protocols and provide evidence for personalized prostate cancer screening in men with key pathogenic germline variants.
Le texte complet de cet article est disponible en PDF.Abbreviations : DRE, PCa, PCRC, MET, NHANES, TRUS, ASAP, GG, NCCN
Plan
| Funding Support: Funding for this work was provided by Select MDx. This work was also supported by the Prostate Cancer Foundation, A. Alfred Taubman Medical Research Institute, and by award number 2P50CA186786-06 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. |
|
| Conflict of interest: TMM receives research funding from MDxHealth and Myriad Genetics. LC is employed by MDxHealth. SDM is a founder and chief scientific officer of InheRET, LLC. |
Vol 156
P. 96-103 - octobre 2021 Retour au numéro
Article précédent
- Estimation of Urinary Frequency: Does Question Phrasing Matter?
- Rachael D Sussman, Christina Escobar, Dora Jericevic, Cheonguen Oh, Alan Arslan, Ricardo Palmerola, Dominique M Pape, Scott W Smilen, Victor W Nitti, Nirit Rosenblum, Benjamin M Brucker
- EDITORIAL COMMENT
- Fatima Karzai, Anna Couvillon, William L Dahut
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?